Table 2.
Characteristics of HDAC inhibitors in sarcoma
| Drug Name | Molecular Formula | Target HDACs |
|---|---|---|
| Vorinostat(SAHA) | C14H20N2O3 | Pan-HDI of class I and IIa |
| Panobinostat(LBH589) | C21H23N3O2 | Pan-HDI of class I, II, and IV |
| Belinostat(PXD101) | C15H14N2O4S | Pan-HDI of class I, II, and IV |
| Romidepsin(FK-228, FR901228, Depsipeptide) | C24H36N4O6S2 | Specific-HDI of class I, specially HDAC 1,2 |
| Entinostat (MS-275, SNDX-275) | C21H20N4O3 | Specific-HDI of HDAC 1, 3 |
| Valproic acid (VPA, Valproate) | C8H15NaO2 | Pan-HDI of Class I and IIa |
| Abexinostat(PCI-24781) | C21H23N3O5 | Pan-HDI of class I and IIb |
| Pracinostat(SB939) | C20H30N4O2 | Pan-HDI of class I, II and IV |
| Sodium phenybutyrate | C10H11O2Na | Pan-HDI of Class I and IIa |
| Quisinostat(JNJ-26481585) | C21H28Cl2N6O2 | Pan-HDI of class I, II and IV |
| LAQ824 | C22H25N3O3 | Pan-HDI of class I, II, IV |
| Sodium Butyrate | C4H7NaO2 | Pan-HDI of class I, IIa, and IV |
| Trichostatin A (TSA) | C17H22N2O3 | Pan-HDI of class I and II |
| Tenovin-6 | C25H34N4O2S | Specific-HDI of Sirtuin 1,2,3 |
| Pyroxamaide (NSC696085) | C13H19N3O3 | Specific-HDI of HDAC 1 |
| MC1742 | C21H21N3O3S | Pan-HDI of Class I and II |
| MC2625 | / | Pan-HDI of class I, II, IV |
| PCI-34051 | C17H16N2O3 | Specific-HDI of HDAC 8 |
| PCI-48012 | / | Specific-HDI of HDAC 8 |
*
FDA approved for hematologic neoplasms not sarcomas Po:by mouth i.v.: intravenous infusion